The numbers are stark: between 50% and 70% of patients prescribed GLP-1 receptor agonists discontinue therapy within 12 months. For telehealth operators managing thousands of patients, this isn’t just a clinical concern — it’s an existential business risk.
Most GLP-1 programs rely on retrospective analysis — looking at who already dropped off — rather than prospective prediction. By the time a patient misses their third refill, they’re gone.
Our analysis of 10,000 patients shows three critical patterns:
The highest-risk period for discontinuation is days 30-90. This is when initial side effects peak (nausea, GI discomfort in ~40% of patients), insurance friction surfaces (prior authorization delays, step therapy requirements), and patients who don’t see early weight response lose motivation.
These patients don’t call to cancel. They simply stop refilling. Their PDC drops from 90% to 60% to 30% over three months, and by the time the program notices, they’ve been off medication for 45+ days.
Mid-treatment insurance denials account for 15% of discontinuations. A patient hits their plan’s step therapy requirement at month 3, or a formulary change removes their medication. Without proactive monitoring, the program only discovers this when the patient calls frustrated.
With real-time PDC tracking and a multi-factor attrition model, operators can identify at-risk patients 30-45 days before they discontinue.
The dropout predictor uses these features:
The model achieves AUC 0.92-0.99 in cross-validation, correctly ranking patients by dropout risk more than 92% of the time.
For a program with 1,000 patients and 25% annual dropout, that’s 250 lost patients × $4,200 = $1.05 million in unrealized value per year.
Even if targeted outreach prevents just 20% of those dropouts, that’s $210,000 in preserved value — from $15 phone calls.
Telehealth companies aren’t pharmaceutical companies. They’re service businesses. Their value proposition is keeping patients on therapy, healthy, and measurably improving.
Without outcomes data, that value proposition is a marketing claim. With it, it’s a business model.
Pathriva provides real-time GLP-1 clinical outcomes analytics. Learn more or calculate your program’s ROI.